Nouveaux traitements de la maladie de Parkinson

Translated title of the contribution: New treatment of Parkinson disease

F. Vingerhoets, J. Ghika, A. Albanese

Research output: Contribution to journalArticlepeer-review


A wealth of new molecules appeared recently for the treatment of Parkinson's disease. New galenic presentations of L-dopa (biphasic Madopar DR) and COMT inhibitors (tolcapone, entacapone) prolong the effects of L- dopa. New potent, well-tolerated dopaminergic agonists (pergolide, ropinirole, pramipexole, and cabergoline) broaden the possibilities treating early and late phases of the disease and may provide some neuroprotection. Finally subthalamic and pallidal stimulations offer major improvements for advanced patients with drug-resistant fluctuations, but, with uncertainty on long term effects. These procedures should stay in the hands of an experienced team of neurologists and neurosurgeons. Neurotransplantation and use of growth factors are still in preclinical phases.

Translated title of the contributionNew treatment of Parkinson disease
Original languageFrench
Pages (from-to)1028-1035
Number of pages8
JournalMedecine et Hygiene
Issue number2209
Publication statusPublished - May 13 1998

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'New treatment of Parkinson disease'. Together they form a unique fingerprint.

Cite this